Study, year | Subjects, N(p/c) | Follow-up(weeks) | Mean age (years) | Type of Dialysis | Baseline MBD Labs* | Phosphate binders | Dosing schedule | Routine of administration | Outcomes | |
---|---|---|---|---|---|---|---|---|---|---|
 |  |  |  |  |  |  | Paricalcitol | Control |  |  |
Sprague 2003 [27] | 263(130/133) | 32 | 56.7 | HD | Ca 2.25 (2.25) mmol/LP 1.91 (1.87) mmol/LPTH 68.7 (71.6) pmol/L | calcium carbonate calcium acetate | Initial dose 0.04 μg/kg and increment of 0.04 μg/kg every 4 weeks. Maximum dose was 0.24 μg. | Initial dose 0.01 μg/kg and increment of 0.01 μg/kg every 4 weeks. Maximum dose was 0.06 μg. | IV | 1,2,3,4 |
Gafor 2009 [26] | 25(13/12) | 12 | 48.2 | HD | Ca 2.29 (2.30) mmol/LP 1.58 (1.65) mmol/LPTH 136.8 (128.1) pmol/L | calcium-containing | Initial dose 0.04 μg/kg and increment of 0.04 μg/kg every 3 weeks. | Initial dose 0.01 μg/kg and increment of 0.01 μg/kg every 3 weeks. | IV | 5,6,7 |
Lund 2010 [25] | 18(9/9) | 5 | 51.1 | HD | Ca 2.17 (2.22) mmol/LP 1.58 (1.71) mmol/LPTH 17.2 (14.6) pmol/L | Sevelamer HCL | Initial dose 0.06 μg/kg | Initial dose 0.02 μg/kg | IV | 6,7 |
Hansen 2011 [24] | 86(45/41) | 16 | 63.7 | HD | Ca 1.15 (1.16) mmol/LaP 1.46 (1.48) mmol/LPTH 57.0 (60.0) pmol/L | calcium-containing sevelamer Lanthanum | Initial dose 9 μg/week, The median (range) final doses for the last 4 weeks: 18.1 μg/week (6.8–60.0 μg/week) | Initial dose 3 μg/week, The median (range) final doses for the last 4 weeks: 5.3 μg/week (0.0–33.0 μg/week) | IV | 1,2,3,4,5,6,7,8 |
Ong 2013 [23] | 66(36/30) | 24 | 46.3 | HD | Ca 2.17 (2.12) mmol/LP 1.87 (1.72) mmol/LPTH 52.5 (59.2) pmol/L | calcium carbonate | Initial dose:(iPTH/12.7)μg, The mean maximal dose 29.6 μg; The mean weekly dose 20.9 μg | Initial dose:(iPTH/38.1)μg, The mean maximal dose 9.9 μg; The mean weekly dose 7.1 μg | PO | 1,2,4,6,7 |
Jamaluddin 2014 [22] | 26(12/14) | 15 | 48.3 | PD | Ca 2.24 (2.25) mmol/LP 1.65 (2.02) mmol/LPTH 85.7 (98.9) pmol/L | calcium carbonate | Initial dose = iPTH/7 every other day up to a maximum initial dose of 32 μg. | Initial dose 5 μg daily. | PO | 1,2 |
Akizawa 2015 [21] | 255(127/128) | 12 | 61.5 | HD | Ca 2.28 (2.28) mmol/LP 1.68 (1.69) mmol/LPTH 55.5 (55.9) pmol/L | calcium-containing;non-Ca containing | Initial dose 2 μg, adjusted ±1 μg based on protocol-specified criteria up to a maximum of 7 μg. | Initial dose 5 μg (iPTH < 53 pmol/L) or 10 μg(iPTH > 53 pmol/L) adjusted ±2.5 μg based on protocol-specified criteria up to a maximum of 20 μg. | IV | 1,2,3 |
Veceric 2016 [28] | 20(10/10) | 12 | 56 | HD | Ca 2.23 (2.04) mmol/L P 1.56 (1.54) mmol/L PTH 63.8 (66.0) pmol/L | non-Ca containing | Initial dose 2 μg; three times per week. | Initial dose 0.5 μg; three times per week. | PO | NR |